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Pancreatic cancer is now becoming a common cause of cancer death with no significant
change in patient survival over the last 10 years. The main treatment options for
pancreatic cancer patients are surgery, radiation therapy and chemotherapy, but there
is now considerable effort to develop new and effective treatments. In recent years,
CRISPR/Cas9 technology has emerged as a powerful gene editing tool with promise,
not only as an important research methodology, but also as a new and effective method
for targeted therapy. In this review, we summarize current advances in CRISPR/Cas9
technology and its application to pancreatic cancer research, and importantly as a
means of selectively targeting key drivers of pancreatic cancer.
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INTRODUCTION
According to the data provided by the North American Association of Central Cancer Registries
(NAACCR), pancreatic cancer is the 12th most common cancer with the 5th worst prognosis in the
United States. It is estimated that there will be 56,770 new cases of pancreatic cancer and 45,750
pancreatic cancer-related deaths in the United States in 2019. Compared to other common cancers,
pancreatic cancer has not seen a significant improvement in patient outcomes, with a 9% 5-year
relative survival (Siegel et al., 2019). Surgery, radiation therapy and chemotherapy are still the main
treatment options for pancreatic cancer, but there is now considerable effort in identifying better
treatment strategies for pancreatic cancer, such as targeted therapy, immune therapy and potentially
CRISPR/Cas9 directed gene therapy.
Currently CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats and
CRISPR-associated protein 9) is emerging as a powerful gene-editing tool with potential in
precision medicine. CRISPR repetitive sequences were first observed by Ishino et al. (1987),
with subsequent work performed by Jinek et al. (2012) proving that an endonuclease can be
directed to cleave target DNA by a two-RNA structure. Since then, CRISPR/Cas9 technology has
rapidly evolved, driving incredible progress in research and clinical applications. Compared to the
other gene-editing technologies, such as meganucleases (MNs), zinc finger nucleases (ZFNs) and
transcription activator-like effector nucleases (TALENs), CRISPR/Cas9 technology has lower cost,
higher efficiency and is less complex in its application (Osborn et al., 2016).
BACKGROUND OF CRISPR/CAS9
CRISPR (clustered regularly interspaced short palindromic repeats) were first described in 1987 by
Ishino et al. (1987) who identified highly conserved nucleotide sequences exhibiting a 14 bp dyad
symmetry at the 3′-end flanking region of the isozyme-converting alkaline phosphatase (iap) gene
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in Escherichia coli. However, the function and biological
importance of CRISPR sequences were not fully understood
until 2007, when Barrangou et al. (2007) exposed Streptococcus
thermophilus to phage and sequenced the resultant phage-
resistant variants. Analysis of the variant DNA revealed that
the bacteria had gained new CRISPR spacers that were derived
from the phage genome. The identification of CRISPR sequences
in bacterial genomes subsequently led to the identification of a
set of homologous genes referred to as CRISPR and associated
(cas) genes that together comprise the CRISPR locus. The
insertion of CRISPR-Cas in the genomes of bacteria infected with
virus suggested that CRISPR-Cas may provide resistance against
phages and that resistance to infection might be enhanced or
decreased by inserting or deleting spacer-phage sequence.
Jinek et al. (2012) in 2012 were the first to demonstrate that
the CRISPR-Cas system could produce a mature CRISPR RNA
(crRNA) and base-paired trans-activating crRNA (tracrRNA)
that together form a two-RNA hybrid structure. This two-RNA
structure could guide CRISPR-associated protein Cas9 to specific
DNA sequences and generate double-stranded (ds) breaks in
target DNA. In 2013, Cong et al. (2013) and Mali et al. (2013)
successfully edited the DNA sequences of the EMX1, PVALB,
PPP1R12C genes in human and the Th gene in mouse using
the CRISPR/Cas9 system. This was the first demonstration of
the power of the CRISPR-Cas9 system to edit the genomes of
eukaryotic cells. Since then, a wealth of research has improved the
CRISPR/Cas9 gene editing tool’s specificity, orthogonality and
multiplexibility in various species, and has led to the development
of new omics applications.
CRISPR/Cas9 technology has been rapidly promoted
and applied in the: generation of animal models; gene
function research; multiplexed mutations; and chromosome
rearrangements. Compared to traditional gene editing tools such
as MNs, ZFNs, TALENs and so on, CRISPR/Cas9 technology
provides the advantage of lower cost, higher efficient and greater
simplicity (Osborn et al., 2016).
APPLICATION OF CRISPR/CAS9 IN
PANCREATIC CANCER
CRISPR/Cas9 Gene Editing in Pancreatic
Cancer
An homologous guide RNA can guide the cas9 nuclease to
target a specific site in the genome. When cas9 is guided to
the target DNA sequence and there is a Protospacer Adjacent
Motif (PAM) sequence downstream, it will cut both strands of
the genome at that location. The cells then repair the break
using two distinct mechanisms: (1) imprecisely by using the
non-homologous end joining (NHEJ) repair pathway, which
causes the insertion or deletion of bases; or (2) accurately
by the homology-directed repair (HDR) pathway. Based on
existing homologous DNA sequences, the HDR pathway can
repair DNA damage accurately by mediating a strand-exchange
process involving the provided DNA sequence as a repair
template to insert a matching DNA sequence into the break.
By inducing NHEJ or HDR, CRISPR/Cas9 knockouts or
knockins can be achieved by deleting, replacing or adding
genetic sequences.
CRISPR/Cas9 system is widely used in pancreatic cancer
research to knock-out genes implicated in disease progression.
Watanabe et al. (2018) used CRISPR/Cas9 to knock out KDM6A
in human Pancreatic ductal adenocarcinoma (PDAC) cell lines
to demonstrate that KDM6A-deficient cells exhibit an aggressive
phenotype. Pessolano et al. (2018) and Belvedere et al. (2016)
showed that, CRISPR/Cas9-directed knock-out of ANXA1 in Mia
PaCa2 cells, resulted in the secretion of fewer extracellular vesicles
and a weak motile phenotype. After knock out of GALNT3 in
Capan1 cells, Barkeer et al. (2018) found that cells formed fewer
tumorspheres, lost their ability to self-renewal, and migrate. Yuza
et al. (2018) demonstrated that knock out of SphK1in PAN02
cells resulted in increased proliferation and migration. C1GALT1
was knocked out of PDAC cells by Chugh et al. (2018) with
CRISPR/Cas9 technology, and the cells showed increased growth,
migration, tumorigenicity, metastasis and expression of Tn and
sTn. There are also some other researches in pancreatic cancer
based on the same strategy by knocking out specific gene of
pancreatic cancer cells, then observe the changes in different
phenotypes (Table 1; Belvedere et al., 2016; Hesler et al., 2016;
Muniyan et al., 2016; Rao et al., 2016; Vorvis et al., 2016; Ayars
et al., 2017; Harada et al., 2017; He et al., 2017; Lal et al.,
2017; Muzumdar et al., 2017; Yu et al., 2017; Zhang et al., 2017;
Barkeer et al., 2018; Chugh et al., 2018; Liu et al., 2018a,b, 2019;
Pessolano et al., 2018; Santoro et al., 2018; Wang et al., 2018;
Watanabe et al., 2018; Yasunaga et al., 2018; Yuza et al., 2018;
Abdalla et al., 2019; Hwang et al., 2019; Li et al., 2019b,c; Stock
et al., 2019). Collectively, these studies show that CRISPR/Cas9
is a very powerful gene editing tool for exploring the function of
defined genes in cell signaling pathways, proliferation, migration,
invasion and potentially chemotherapy resistance of pancreatic
cancer. By using CRISPR/Cas9 technology to knock out target
genes and characterize phenotypic changes, we can develop a
better understanding of biological roles played by target genes,
identify potential treatment targets and/or better treatment
strategy for pancreatic cancer. But there is still a long way to
go before CRISPR/Cas9 technology can be used as an effective
treatment strategy in the clinic.
Gene knockins by CRISPR/Cas9 are also quite important for
exploring gene functions in tumorigenesis and development and
commonly used for building specific gene expression stem cells
and animal models in recently years (Yang et al., 2013; Platt et al.,
2014; Ma et al., 2017; Li et al., 2019a). But due to the complicated
procedure and time consumption, it is still more common to
generate gene expressing cells by building gene expression vectors
and transducing the vector into cells via retrovirus or lentivirus
in pancreatic cancer research (Li et al., 2019c; Sharma et al., 2019;
Watanabe et al., 2019).
CRISPR Pooled Library Screening in
Pancreatic Cancer
Using a sgRNA library to perform loss-of-function (LoF)
phenotypic screens is a powerful way to identify novel protein
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TABLE 1 | Recent researches of gene function in pancreatic cancer by CRISPR/Cas9 knockouts of pancreatic cancer cells.
sgRNA target Cell lines Effect References
KDM6A BxPC3, PANC1 proliferation↑, migration↑, invasion↑ Watanabe et al., 2018
ANXA1 MIA PaCa-2 migration↓, invasion↓, extracellular vesicles↓ Pessolano et al., 2018;
Belvedere et al., 2016
SphK1 SphK2 PAN02 proliferation↑, migration↑, survival of mice↓ proliferation↓, migration↓,
survival of mice↑
Yuza et al., 2018
GALNT3 Capan1 proliferation↓, migration↓ Barkeer et al., 2018
C1galt1 KPC, KPCC proliferation↑, migration↑, tumorigenicity↑, metastasis↑ Chugh et al., 2018
ARID1A HPDE H2K27ac marks↑ Wang et al., 2018
GPRC5a MIA PaCa-2, TB32047 proliferation↓, migration↓, chemotherapy resistance↓ Liu et al., 2018a
ECT2 MIA PaCa-2 proliferation↓, migration↓ Liu et al., 2018b
ATG12 MIA PaCa-2, AR42J expression of duct cell markers↑, expression of acinar cell markers↓ Yasunaga et al., 2018
KRAS A13,8988T, PANC1, KP-4,
MM1402, PACO9, PACO19
exhibit PI3K dependence Muzumdar et al., 2017
HuR MIA PaCa-2 apoptosis↑, unable to engraft tumors in vivo Lal et al., 2017
Hs 776T unable to engraft tumors in vivo
HCT116 proliferation↓
Rab11-FIP4 PANC-1 proliferation↓, invasion↓, metastasis↓ He et al., 2017
IRAK4 PANC-1, Pa01c anchorage-independent (AI) growth↓ Zhang et al., 2017
CYR61 MIA PaCa-2, PANC1 hENT1 and hCNT3 expression↑, cellular uptake of gemcitabine↑,
gemcitabine-induced apoptosis↑
Hesler et al., 2016
MUC16 Capan1 expression of Thomsen-Friedenreich (TF/T) and Thomsen-nouvelle (Tn)
carbohydrate antigens↓
Muniyan et al., 2016
FOXA2 PANC-1 tumorigenicity↑, aggressiveness↑ Vorvis et al., 2016
GCNT3 MIA PaCa, BxPC-3, PANC-1 proliferation↓, spheroid formation↓ Rao et al., 2016
CTTN PANC-1, BxPC-3 migration↓, invasion↓ Stock et al., 2019
CRABP-II PANC-1 migration↓, invasion↓, expression of interleukin 8 (IL-8), MMP-2 and MMP-14↓ Yu et al., 2017
HO-1 Capan-1 Under hypoxia, proliferation↓, sensitivity to gemcitabine↑ Abdalla et al., 2019
WNT5B PANC-1 migration↓, invasion↓ Harada et al., 2017
CDH17 Panc02-H7 Proliferation, colony formation and motility↓ Liu et al., 2019
EI24 MIA PaCa-2 Proliferation↓ Hwang et al., 2019
HO1 CD18/HPAF, COLO 357, Capan-1,
Mia PaCa-2
under hypoxia, proliferation↓, sensitive to gemcitabine↑ Abdalla et al., 2019
IL2RG TB32043, bkpc58 Tumor growth in mice↓, JAK3 expression in orthotopic tumors↓ Ayars et al., 2017
HIF-1α BxPC-3 Metastasis↓ Li et al., 2019b
MEKK3 Panc-1, AsPC1 EMT and cell migration↓, tumor growth↓, mice overall survival↑ Santoro et al., 2018
ERBB2 HPAFII, CAPAN1, Mia PaCa-2
(all ERBB2-amplified)
ERBB2 signaling, colony formation, anchorage-independent growth and tumor
xenograft formation↓
Li et al., 2019c
↑, up-regulation; and ↓, down-regulation.
functions in specific growth conditions. The main strategy of
CRISPR pooled library screening involves the use of thousands
of plasmids in one CRISPR pooled library, with each plasmid
containing an sgRNA targeting a specific gene. The sgRNAs
first needs to be delivered into a sufficient number of cells via
lentivirus or retrovirus transduction. The transduced cells are
then grown under specific conditions to select a phenotype of
interest. After the selection, the genomic DNA is isolated from
the cells, and next-generation sequencing (NGS) performed.
The NGS data are then mapped to a pre-complied library
comprising the gene-specific gRNAs and the results analyzed by
computational tool such as MAGeCK (Model-based Analysis of
Genome-wide CRISPR-Cas9 Knockout) (Li et al., 2014). Genes
responsible for the observed phenotype are then identified by
comparing control and selected gRNAs.
Several studies have now used CRISPR pooled library
screening in pancreatic cancer cells (Table 2; Steinhart et al.,
2017; Wang et al., 2017; Szlachta et al., 2018; Bakke et al.,
2019; Sarr et al., 2019). Bakke et al. (2019) transduced PANC-
1-cas9 cells with human sgRNA library Brunello and selected
the cells with 100 nM gemcitabine for 6 days. PSMA6 was
identified as a top hit after comparing NGS results obtained
for gemcitabine selected samples and control samples. PSMA6
inhibition was subsequently shown to result in apoptosis and
reduced spheroid formation. In Steinhart et al. (2017), a TKO
gRNA library was transduced into HPAF-II-Cas9 cells, and cells
screened at different time points to identify the set of fitness
genes required for proliferation. They used the BAGEL algorithm
(Hart and Moffat, 2016) to calculate a log Bayer factor (BF) for
each gene. This analysis identified several core components of
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TABLE 2 | Recent researches of CRISPR pooled library screening in pancreatic cancer.
Hit genes Effect Cell line Library Gene/sgRNA number Selection condition References
PSMA6 apoptosis↑,
spheroid
formation↓
PANC-1 Human sgRNA library Brunello
(addgene No. 73178)
19114/76441 100 nM gemcitabine for
6 days
Bakke et al., 2019
Wnt pathway
genes, FZD5
Proliferation↓ HPAF-II,
AsPC-1,
PaTu8988S
Toronto KnockOut (TKO) CRISPR
Library (addgene
No. 1000000069)
17232/91320 different time point (Day 15,
27, 31, 35)
Steinhart et al., 2017
CIC, ATXN1L sensitivity to
trametinib↓
PATU8902 GeCKOv2 library (addgene
No. 1000000049)
19050/123411 100 nM trametinib for
14 days
Wang et al., 2017
PATU8988T Avana library Doench et al., 2016 18675/110257 10 nM trametinib for 14 days
CENPE, RRM1 sensitivity to
trametinib↑
PDX366 Nuclear proteins gRNA sub-pool
library (addgene No. 51047)
7114/73151 MEK and CENPE inhibitor
treatment in 6–8-week-old
mail athymic nude mice
Szlachta et al., 2018
DCK, DCTPP1 sensitivity to
NUC-1031,
gemcitabine↓
Mia PaCa-2,
A2780
GeCKOv2 library (addgene
No. 1000000049)
19050/123411 15 nM gemcitabine or 65 nM
NUC-1031 for 14 days or
21 days
Sarr et al., 2019
↑, up-regulation; and ↓, down-regulation.
the Wnt pathway, including WLS, CTNNB1, TCF7L2, LRP5, and
PORCN, and 3 Frizzled (FZD) receptors and Wnts encoding
genes, FZD5, WNT7B, WNT10A, as essential genes for HPAF-
II cell proliferation. These results were subsequently validated in
AsPC-1 and PaTU8988S cell lines, identifying the Wnt pathway
as an important mediator of pancreatic cancer cell proliferation.
These screen results also revealed that the proliferation and/or
survival of RNF43-mutant PDAC cells are selectively dependent
on Wnt-β-catenin signaling. Wang et al. (2017) also performed
genome scale CRISPR-Cas9 knockout screens in PATU8902 and
PATU8988T cell lines to identify genes capable of promoting
proliferation or survival in the context of MAPKi by deletion.
They transduced the GeCKOv2 library into PATU8902 cells,
and Avana library into PATU8988T cells. PATU8902 cells
were treated with MEK1/2 inhibitor trametinib 100 nM and
PATU8988T cells were treated with 10 nM trametinib. Both
cell lines were treated with trametinib for 14 days. Genomic
DNA was then isolated and NGS performed. CIC and ATXN1L
were identified by comparative analysis, indicating that loss of
both CIC and ATXN1L can reduce sensitivity to trametinib
treatment in vivo.
These studies successfully demonstrate that novel gene
functions can be identified using CRISPR pooled library
screening with specific selection conditions, thereby providing
a very powerful methodology for identifying therapeutic
vulnerabilities in pancreatic cancer cells and pointing the way
toward new treatment strategies. But there are also several
factors that can affect the accuracy of the screening results.
Based on different size of libraries, different number of cells
are required to be transduced for maintaining the coverage
of the libraries. Weak selection conditions may provide more
comprehensive results, but will also produce false positive
which may not be causative in phenotypic changes. Different
selection methods may also drive experimental variability.
The deep sequencing quality and the selection of data
analysis tools will also play very important roles in screening
accuracy. Therefore, results still need to be validated using
orthogonal methods.
Current Status of CRISPR/Cas9 Gene
Therapy for Pancreatic Cancer
In pancreatic cancer gene therapy, there are several current
developments including gene-based tumor cell sensitization
to chemotherapy, vaccination, and adoptive immunotherapy
(Rouanet et al., 2017). But recently the CRISPR/Cas9 genome
editing method has been utilized in several pancreatic cancer
studies due to its safety and efficacy. CRISPR/Cas9 gene therapy
could be potentially used both ex vivo and in vivo. In ex vivo
therapy, cells could be isolated and modified outside of the body,
and then transplanted back into the body. In in vivo therapy,
genetic materials could be directly injected into the body (Song,
2017). Chiou et al. (2015) built in vivo pancreatic cancer models
via retrograde pancreatic ductal injection of either adenoviral-
Cre and lentiviral-Cre vectors. This technique could establish
new therapies for pancreatic cancer. Accordingly, CRISPR/Cas9
technology is providing great hope for the treatment of
monogenic diseases, degenerative diseases and HIV infection,
and several CRISPR/Cas9 clinical trials have been performed, but
there is still a long way to go before the CRISPR/Cas9 technique
is used to treat pancreatic cancer patients. Several challenges still
need to be considered. For example, which crucial gene(s) should
be targeted? And the accuracy, efficiency and safety need to be
increased to meet the requirement of clinical application.
LIMITATIONS OF THE CRISPR/CAS9
APPLICATION
CRISPR/Cas9 is widely applied not only in pancreatic
cancer research, but also other cancer settings to further
our understanding of disease progression, identify mechanisms
of drug resistance and to uncover potential therapeutic
vulnerabilities. However, there are still some limitations to this
technology that need to be considered before CRISPR/Cas9 is
used in the clinical practice. Potential off-target effect are a major
concern and need to be minimized to ensure safety. Considerable
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effort has been made to reduce off-target effects. Ran et al.
(2013) combined the D10A mutant nickase Cas9 (Cas9n)
with a pair of offset sgRNAs which are complementary to
opposite strands of the target site. This approach improved
the specificity of CRISPR/Cas9 editing without sacrificing on-
target cleavage efficiency. Shen et al. (2014) used Cas9(D10A)
or Cas9(H840A) to perform AR-A and AR-B gene editing in
mouse fibroblast cells. T7EN cleavage assay and TA cloning
were performed to detect the modification of the AR gene,
and off-target effects were not found. Tsai et al. (2014)
demonstrated that dimeric RNA-guided FokI Nucleases (RFNs)
could recognize extended sequences and edit endogenous genes
with high efficiencies.
CONCLUSION AND OUTLOOK
Compare to the other gene-editing technologies, CRISPR/Cas9
technology involves lower costs, higher efficiency and simplicity
of use. It is widely used to characterize gene function(s) under
specific selection conditions and is gaining traction in pancreatic
cancer research. But there is still a long way before this technology
can be used as a selective gene therapy in the clinics. Improving
the specificity of cas9 gene editing, reducing off-target effects and
increasing the efficiency of cell transduction and cell targeting
are all important challenges that need to be overcome. As a
maturing gene editing technology, CRISPR/Cas9 represents a
“game changer” for scientific research and an exciting targeted
therapy for pancreatic cancer.
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